Jackson, David J.
Korn, Stephanie
Mathur, Sameer K.
Barker, Peter
Meka, Venkata G.
Martin, Ubaldo J.
Zangrilli, James G.
Funding for this research was provided by:
AstraZeneca
Article History
First Online: 2 April 2020
Compliance with Ethical Standards
:
: David J. Jackson has received advisory board and speaker fees from AstraZeneca. Stephanie Korn is a study investigator and has served on advisory boards for and received honoraria for symposia lectures from AstraZeneca. Sameer K. Mathur has received consulting and speaker fees from AstraZeneca. Peter Barker, Venkata G. Meka, Ubaldo J. Martin, and James G. Zangrilli are employees of AstraZeneca, the manufacturer of benralizumab, and each own stock in AstraZeneca.
: The development of this review was funded by AstraZeneca.
: All patients enrolled in the trials used to generate the data reported here provided written informed consent at enrollment. All source studies were conducted in accordance with the principles of the Declaration of Helsinki and were consistent with the International Council for Harmonisation/Good Clinical Practice. Additional information is provided in the electronic supplementary material.
: Data underlying the findings described in this manuscript may be requested in accordance with AstraZeneca’s data-sharing policy described atExternalRef removed.